Antoni Hurtado

Dr. Antoni Hurtado

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AHAntoni Hurtado
Antoni Hurtado
KHKelly A Holmes
Kelly A Holmes
CRCaryn S Ross-Innes
Caryn S Ross-Innes
DSDominic Schmidt
Dominic Schmidt
JCJason S Carroll
Jason S Carroll
Jason Carroll and colleagues report that the forkhead protein FOXA1 is an important determinant of estrogen receptor binding and show that expression of FOXA1 in non–breast cancer cells is sufficient to confer estrogen receptor binding and response to endocrine treatment. Estrogen receptor-α (ER) is the key feature of most breast cancers and binding of ER to the genome correlates with expression of the Forkhead protein FOXA1 (also called HNF3α). Here we show that FOXA1 is a key determinant that can influence differential interactions between ER and chromatin. Almost all ER-chromatin interactions and gene expression changes depended on the presence of FOXA1 and FOXA1 influenced genome-wide chromatin accessibility. Furthermore, we found that CTCF was an upstream negative regulator of FOXA1-chromatin interactions. In estrogen-responsive breast cancer cells, the dependency on FOXA1 for tamoxifen-ER activity was absolute; in tamoxifen-resistant cells, ER binding was independent of ligand but depended on FOXA1. Expression of FOXA1 in non-breast cancer cells can alter ER binding and function. As such, FOXA1 is a major determinant of estrogen-ER activity and endocrine response in breast cancer cells.

10 March 2010 in Genome Research
Verified
Journal Article
Open access
PDF file
DSDominic Schmidt
Dominic Schmidt
PSPetra C. Schwalie
Petra C. Schwalie
CRCaryn S. Ross-Innes
Caryn S. Ross-Innes
AHAntoni Hurtado
Antoni Hurtado
GBGordon D. Brown
Gordon D. Brown
DODuncan T. Odom
Duncan T. Odom
The cohesin protein complex holds sister chromatids in dividing cells together and is essential for chromosome segregation. Recently, cohesin has been implicated in mediating transcriptional insulation, via its interactions with CTCF. Here, we show in different cell types that cohesin functionally behaves as a tissue-specific transcriptional regulator, independent of CTCF binding. By performing matched genome-wide binding assays (ChIP-seq) in human breast cancer cells (MCF-7), we discovered thousands of genomic sites that share cohesin and estrogen receptor alpha (ER) yet lack CTCF binding. By use of human hepatocellular carcinoma cells (HepG2), we found that liver-specific transcription factors colocalize with cohesin independently of CTCF at liver-specific targets that are distinct from those found in breast cancer cells. Furthermore, estrogen-regulated genes are preferentially bound by both ER and cohesin, and functionally, the silencing of cohesin caused aberrant re-entry of breast cancer cells into cell cycle after hormone treatment. We combined chromosomal interaction data in MCF-7 cells with our cohesin binding data to show that cohesin is highly enriched at ER-bound regions that capture inter-chromosomal loop anchors. Together, our data show that cohesin cobinds across the genome with transcription factors independently of CTCF, plays a functional role in estrogen-regulated transcription, and may help to mediate tissue-specific transcriptional responses via long-range chromosomal interactions.

1 December 2008 in Nature
Verified
Journal Article
Closed access
PDF file
AHAntoni Hurtado
Antoni Hurtado
KHKelly A. Holmes
Kelly A. Holmes
TGTimothy R. Geistlinger
Timothy R. Geistlinger
IHIain R. Hutcheson
Iain R. Hutcheson
RNRobert I. Nicholson
Robert I. Nicholson
JCJason S. Carroll
Jason S. Carroll

9 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
TFThomas Fleischer
Thomas Fleischer
XTXavier Tekpli
Xavier Tekpli
AMAnthony Mathelier
Anthony Mathelier
SWShixiong Wang
Shixiong Wang
DNDaniel Nebdal
Daniel Nebdal
VKVessela N. Kristensen
Vessela N. Kristensen
Breast cancers exhibit genome-wide aberrant DNA methylation patterns. To investigate how these affect the transcriptome and which changes are linked to transformation or progression, we apply genome-wide expression–methylation quantitative trait loci (emQTL) analysis between DNA methylation and gene expression. On a whole genome scale, in cis and in trans, DNA methylation and gene expression have remarkably and reproducibly conserved patterns of association in three breast cancer cohorts (n = 104, n = 253 and n = 277). The expression–methylation quantitative trait loci associations form two main clusters; one relates to tumor infiltrating immune cell signatures and the other to estrogen receptor signaling. In the estrogen related cluster, using ChromHMM segmentation and transcription factor chromatin immunoprecipitation sequencing data, we identify transcriptional networks regulated in a cell lineage-specific manner by DNA methylation at enhancers. These networks are strongly dominated by ERα, FOXA1 or GATA3 and their targets were functionally validated using knockdown by small interfering RNA or GRO-seq analysis after transcriptional stimulation with estrogen.

18 February 2011 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
DHDaniel G. Holland
Daniel G. Holland
ABAngela Burleigh
Angela Burleigh
AGAnna Git
Anna Git
MGMae A. Goldgraben
Mae A. Goldgraben
PPPedro A. Perez‐Mancera
Pedro A. Perez‐Mancera
CCCarlos Caldas
Carlos Caldas
The telomeric amplicon at 8p12 is common in oestrogen receptor‐positive (ER+) breast cancers. Array‐CGH and expression analyses of 1172 primary breast tumours revealed that ZNF703 was the single gene within the minimal amplicon and was amplified predominantly in the Luminal B subtype. Amplification was shown to correlate with increased gene and protein expression and was associated with a distinct expression signature and poor clinical outcome. ZNF703 transformed NIH 3T3 fibroblasts, behaving as a classical oncogene, and regulated proliferation in human luminal breast cancer cell lines and immortalized human mammary epithelial cells. Manipulation of ZNF703 expression in the luminal MCF7 cell line modified the effects of TGFβ on proliferation. Overexpression of ZNF703 in normal human breast epithelial cells enhanced the frequency of in vitro colony‐forming cells from luminal progenitors. Taken together, these data strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer.

23 November 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MHMari Kyllesø Halle
Mari Kyllesø Halle
ITIngvild Løberg Tangen
Ingvild Løberg Tangen
HBHege F. Berg
Hege F. Berg
EHErling Andre Hoivik
Erling Andre Hoivik
KMKaren K Mauland
Karen K Mauland
CKCamilla Krakstad
Camilla Krakstad
Despite successful implementation of drugs targeting the human epidermal growth factor receptor 2 (HER2) receptor in breast and gastric cancers, the potential of HER2 as a therapeutic target in other cancers has been less studied, including endometrial cancer. We investigated expression levels of HER2 (ERBB2) in a large cohort of endometrial cancer lesions, also including complex atypical hyperplasia and metastatic lesions. 67 precursor lesions, 790 primary endometrial cancers and 383 metastatic lesions were investigated for HER2 expression in relation to clinicopathologic features and outcome. Protein levels were assessed by immunohistochemistry (using the HercepTest and staining index (SI) criteria), mRNA levels by microarrays and amplification status by chromogenic in situ hybridisation. High HER2 protein levels were significantly associated with features of aggressive disease and increased mRNA ERBB2 levels. HER2 expression defined by the SI proved to be a better predictor of survival compared with the HercepTest. A discordant HER2 expression pattern between paired primary and metastatic lesions was detected, revealing substantial reduction in HER2 expression from primary to metastatic disease. Loss of HER2 expression is common in metastatic endometrial cancer lesions and assessment of HER2 levels in the metastatic lesions may be important to define the potential benefit of anti-HER2 treatments in endometrial cancer patients.